Biomarkers for Risk Stratification in Lung Cancer
NCT03774758
This study is recruiting at 3 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Nodule Solitary Pulmonary
- Non-small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of California, San Francisco
- Last updated on ClinicalTrials.gov
- October 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- San Francisco VA Medical Center · San Francisco, CA
- University of California, San Francisco · San Francisco, CA
- Zuckerberg San Francisco General Hospital and Trauma Center · San Francisco, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.